Brief: Lexeo Therapeutics Announces Regulatory Update And Registrational Trial Design For LX2006 Gene Therapy In Friedreich Ataxia
15/06/2026 12:12
BRIEF-Lexeo Therapeutics Announces Regulatory Update And Registrational Trial Design For LX2006 Gene Therapy In Friedreich Ataxia June 15 (Reuters) - Lexeo Therapeutics Inc LXEO.O:
LEXEO THERAPEUTICS ANNOUNCES REGULATORY UPDATE AND REGISTRATIONAL TRIAL DESIGN FOR LX2006 GENE THERAPY IN FRIEDREICH ATAXIA
LEXEO THERAPEUTICS - TOPLINE DATA READOUT EXPECTED IN H2 2027; BLA SUBMISSION IN H1 2028
LEXEO THERAPEUTICS - SUNRISE-FA 2 INITIATION ON TRACK FOR Q2 2026; FIRST PATIENT EXPECTED BY END OF JUNE
Source text: ID:nGNX8Wb9Td
Further company coverage: LXEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease